Aquinnah Pharmaceuticals receives $3.4 million grant from NINDS to advance new therapies for ALS

(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

AbstractMany  central nervous system diseases currently lack effective treatment and are often associated with defects in microvascular function, including a failure to match the energy supplied by the blood to the energy used on neuronal computation, or a breakdown of the blood–brain barrier. Pericytes, an u nder-studied cell type located on capillaries, are of crucial importance in regulating diverse microvascular functions, such as angiogenesis, the blood–brain barrier, capillary blood flow and the movement of immune cells into the brain. They also form part of the “glial” scar isolating dam...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
This study may serve disabled people to control assistive devices in natural, unobtrusive, speedy and reliable manner. Moreover, it is expected that GKP-based TMI could be a collaboration channel for traditional electroencephalography (EEG)-based brain computer interfaces which have significant inadequacies arisen from the EEG signals.
Source: Biocybernetics and Biomedical Engineering - Category: Biomedical Engineering Source Type: research
CONCLUSION: The BCI and PoE technology, combined with smart home system, overcoming the shortcomings of traditional systems and achieving home applications management rely on EEG signal. In this paper, we proposed an online steady-state visual evoked potential (SSVEP) based BCI system on controlling several smart home devices. PMID: 30103356 [PubMed - as supplied by publisher]
Source: Technology and Health Care - Category: Medical Devices Authors: Tags: Technol Health Care Source Type: research
Conclusions Disability proved to be the main variable related to the presence of sexual dysfunction. Patients with ALS had the worst rates of sexual dysfunction. Patients with MS were similar to the control group. As for the PD group, no patient had normal sexuality. Finally, in stroke patients, the presence of comorbidities and their treatment may have negatively influenced sexuality. These findings showed that patients with chronic neurological diseases have sexual dysfunction and underscore the need for neurologists to know and address this problem.RESUMO Las enfermedades neurol ógicas crónicas generan dis...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
ABSTRACT Yawning is a stereotyped physiological behavior that can represent a sign or symptom of several conditions, such as stroke, parakinesia brachialis oscitans, parkinsonism, Parkinson ’ s disease and epilepsy. More rarely, it can occur in patients with intracranial hypertension, brain tumor, multiple sclerosis, migraine, Chiari malformation type I, and amyotrophic lateral sclerosis. Drug-induced yawning is an uncommon clinical condition and yawning in patients with autism or schizophrenia is very rare. The aim of this review is to describe in detail the occurrence of the phenomenon in such conditions, and its &...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
Abstract During these last years, the CB2 cannabinoid receptor has emerged as a potential anti-inflammatory target in diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, ischemic stroke, autoimmune diseases, osteoporosis, and cancer. However, the development of clinically useful CB2 agonists reveals to be very challenging. Allosterism and biased-signaling mechanisms at CB2 receptor may offer new avenues for the development of improved CB2 receptor-targeted therapies. Although there has been some exploration of CB1 receptor activation by new CB1 allosteric or biased-signaling l...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
This article discusses the preclinical pharmacology, pharmacokinetics, safety profile, clinical studies and drug interactions of edaravone (Radicava) in ALS. PMID: 29998226 [PubMed - in process]
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-lab...
Source: PMandR - Category: Rehabilitation Source Type: research
This study may serve disabled people to control assistive devices in natural, unobtrusive, speedy and reliable manner. Moreover, it is expected that GKP-based TMI could be a collaboration channel for traditional electroencephalography (EEG)-based brain computer interfaces which have significant inadequacies arisen from the EEG signals.
Source: Biocybernetics and Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-lab...
Source: PMandR - Category: Rehabilitation Source Type: research
More News: ALS | Biology | Brain | Grants | Neurology | Stroke